Literature DB >> 1745022

Acute intradialytic well-being: results of a clinical trial comparing polysulfone with cuprophan. Bergamo Collaborative Dialysis Study Group.

.   

Abstract

We conducted a multicenter, randomized, double-blind, controlled clinical trial to compare the effects of a synthetic, high-flux polysulfone membrane with a standard cuprophan one on acute clinical complications during a diffusive dialysis procedure. The principal end-point, that is, the number of hypotensive episodes, was similar in polysulfone (39; 23.8%) and cuprophan (32; 19.5%). Likewise, no significant difference was found between the two membranes as far as the secondary end-point was concerned, that is, the effect on headache, nausea, pruritus and sense of well-being. We conclude that high-flux polysulfone, acutely used in standard diffusive dialysis, has no favorable influence on hypotensive episodes and does not affect some typical dialysis-related symptoms any differently from cuprophan membrane. The need is stressed for well-controlled studies specifically designed to assess the worth of new dialysis techniques and materials that may vastly raise the cost of dialysis treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1745022     DOI: 10.1038/ki.1991.265

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  3 in total

Review 1.  High-flux versus low-flux membranes for end-stage kidney disease.

Authors:  Suetonia C Palmer; Kannaiyan S Rabindranath; Jonathan C Craig; Paul J Roderick; Francesco Locatelli; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

Review 2.  Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.

Authors:  A M Macleod; M Campbell; J D Cody; C Daly; C Donaldson; A Grant; I Khan; K S Rabindranath; L Vale; S Wallace
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

3.  Laboratory and dialysis characteristics in hemodialysis patients suffering from chronic itch--results from a representative cross-sectional study.

Authors:  Elke Weisshaar; Melanie Weiss; Jutta Passlick-Deetjen; Ulrich Tschulena; Klaudia Maleki; Thomas Mettang
Journal:  BMC Nephrol       Date:  2015-11-04       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.